How to buy Zai Lab stock | $100.75

Zai Lab Limited is a biotechnology business based in the US. Zai Lab shares (ZLAB) are listed on the NASDAQ and all prices are listed in US Dollars. Zai Lab employs 1,194 staff and has a trailing 12-month revenue of around 0.00.

Zai Lab stock price (NASDAQ: ZLAB)

Use our graph to track the performance of ZLAB stocks over time.

Zai Lab shares at a glance

• Key figures

Information last updated 2021-10-17.

Latest market close	$100.75
52-week range	$80.46 - $193.54
50-day moving average	$120.74
200-day moving average	$148.17
Wall St. target price	$212.07
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-6.23

Buy Zai Lab shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Zai Lab stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zai Lab price performance over time

Historical closes compared with the close of $100.75 from 2021-10-22

1 week (2021-10-15)	-1.23%
1 month (2021-09-24)	-15.94%
3 months (2021-07-23)	-32.83%
6 months (2021-04-23)	-41.79%

1 year (2020-10-23)	15.54%
2 years (2019-10-23)	238.20%
3 years (2018-10-23)	553.80%
5 years (2016-10-20)	N/A

Zai Lab financials

Revenue TTM	$86.8 million
Gross profit TTM	$32.2 million
Return on assets TTM	-29.12%
Return on equity TTM	-50.21%
Profit margin	0%
Book value	$17.64
Market capitalisation	$9.8 billion

TTM: trailing 12 months

Shorting Zai Lab shares

There are currently 3.1 million Zai Lab shares held short by investors – that's known as Zai Lab's "short interest". This figure is 21% up from 2.5 million last month.

There are a few different ways that this level of interest in shorting Zai Lab shares can be evaluated.

Zai Lab's "short interest ratio" (SIR)

Zai Lab's "short interest ratio" (SIR) is the quantity of Zai Lab shares currently shorted divided by the average quantity of Zai Lab shares traded daily (recently around 585699.61685824). Zai Lab's SIR currently stands at 5.22. In other words for every 100,000 Zai Lab shares traded daily on the market, roughly 5220 shares are currently held short.

However Zai Lab's short interest can also be evaluated against the total number of Zai Lab shares, or, against the total number of tradable Zai Lab shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zai Lab's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Zai Lab shares in existence, roughly 30 shares are currently held short) or 0.0396% of the tradable shares (for every 100,000 tradable Zai Lab shares, roughly 40 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Zai Lab.

Find out more about how you can short Zai Lab stock.

Zai Lab share dividends

We're not expecting Zai Lab to pay a dividend over the next 12 months.

Zai Lab share price volatility

Over the last 12 months, Zai Lab's shares have ranged in value from as little as $80.46 up to $193.54. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zai Lab's is 1.2401. This would suggest that Zai Lab's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Zai Lab overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; TPX-0022, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin-17; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. It has development, license, and collaboration agreements with GlaxoSmithKline; Paratek Bermuda, Ltd. ; Five Prime Therapeutics, Inc. ; Entasis Therapeutics Holdings, Inc.

Frequently asked questions

What percentage of Zai Lab is owned by insiders or institutions?
Currently 0.017% of Zai Lab shares are held by insiders and 77.326% by institutions. How many people work for Zai Lab?
Latest data suggests 1,194 work at Zai Lab. When does the fiscal year end for Zai Lab?
Zai Lab's fiscal year ends in December. Where is Zai Lab based?
Zai Lab's address is: Building 1, Jinchuang Plaza, Shanghai, China, 201210 What is Zai Lab's ISIN number?
Zai Lab's international securities identification number is: US98887Q1040 What is Zai Lab's CUSIP number?
Zai Lab's Committee on Uniform Securities Identification Procedures number is: 894789106